Read this manager's filing book
Disclosed positions
Cormorant Asset Management, LP: source evidence dated 2026-08-15T03:59:59.999Z.
- Issuer
- PRAXIS PRECISION MEDICINES I
- Ticker
- PRAX
- Class
- COM NEW
- Reported value
- $214,265,600
- Reported amount
- 640,000
- Unit
- SH
- Option
- None
The displayed owner or issuer and source fields identify the receipt to verify; keep reporting and availability dates separate.
What was reported for this quarter?
13F positions are dated quarter-end holdings, with later publication and possible amendments. Read report period and availability before calling them current.
SEC 13F-HR: 0001583977-26-000007Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filings
Open the effective filing receipt and inspect shares, value and any put/call classification separately.
Browse institutional filingsKeep reporting dates and units beside the answer, and inspect its original citations.
Disclosed positions
See the complete disclosed positions
Scroll sideways to compare all columns. Select a heading to sort.
| PRAXIS PRECISION MEDICINES I | PRAX | COM NEW | $214,265,600 | 640,000 | SH | None |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | COM NEW | $136,234,886 | 17,878,594 | SH | None |
| PARABILIS MEDICINES INC | PBLS | COM | $126,329,300 | 4,615,612 | SH | None |
| RAPPORT THERAPEUTICS INC | RAPP | COM | $110,738,900 | 2,657,521 | SH | None |
| ERASCA INC | ERAS | COM | $109,920,000 | 6,000,000 | SH | None |
| EDGEWISE THERAPEUTICS INC | EWTX | COM | $101,981,300 | 2,510,000 | SH | None |
| EYEPOINT INC | EYPT | COM NEW | $100,100,000 | 7,000,000 | SH | None |
| ALUMIS INC | ALMS | COM | $92,456,671 | 3,285,596 | SH | None |
| ABIVAX SA | ABVX | SPONSORED ADS | $89,950,500 | 675,000 | SH | None |
| DIANTHUS THERAPEUTICS INC | DNTH | COM | $73,110,000 | 750,000 | SH | None |
| BRIGHT MINDS BIOSCIENCES INC | DRUG | COM NEW | $63,180,000 | 900,000 | SH | None |
| MOONLAKE IMMUNOTHERAPEUTICS | MLTX | CLASS A ORD | $62,409,781 | 3,205,433 | SH | None |
| BIOAGE LABS INC | BIOA | COM | $58,593,729 | 2,390,605 | SH | None |
| ORUKA THERAPEUTICS INC | ORKA | COM | $50,757,968 | 533,340 | SH | None |
| ADLAI NORTYE LTD | ANL | SPONSORED ADS | $45,749,634 | 3,978,229 | SH | None |
| BRIDGEBIO PHARMA INC | BBIO | COM | $40,964,000 | 550,000 | SH | None |
| TANGO THERAPEUTICS INC | TNGX | COM | $40,638,000 | 1,300,000 | SH | None |
| BIOHAVEN LTD | BHVN | COM | $38,836,800 | 2,610,000 | SH | None |
| AGOMAB THERAPEUTICS NV | AGMB | SPONSORED ADS | $32,000,217 | 2,465,348 | SH | None |
| MBX BIOSCIENCES INC | MBX | COM | $30,360,000 | 550,000 | SH | None |
| CLIMB BIO INC | CLYM | COM | $27,462,240 | 2,106,000 | SH | None |
| OLEMA PHARMACEUTICALS INC | OLMA | COM | $26,896,500 | 2,150,000 | SH | None |
| DAMORA THERAPEUTICS INC | DMRA | COM | $26,010,000 | 1,000,000 | SH | None |
| PHARVARIS N V | PHVS | COM | $25,935,000 | 750,000 | SH | None |
| CORBUS PHARMACEUTICALS HLDGS | CRBP | COM NEW | $21,995,828 | 2,344,971 | SH | None |
| SPYRE THERAPEUTICS INC | SYRE | COM NEW | $19,975,500 | 225,000 | SH | None |
| DEFINIUM THERAPEUTICS INC | DFTX | COM SHS | $18,816,000 | 400,000 | SH | None |
| NEWAMSTERDAM PHARMA COMPANY | NAMS | ORDINARY SHARES | $16,945,000 | 500,000 | SH | None |
| ROIVANT SCIENCES LTD | ROIV | SHS | $16,810,250 | 475,000 | SH | None |
| CABALETTA BIO INC | CABA | COM | $15,550,000 | 5,000,000 | SH | None |
| HELIX ACQUISITION CORP III | HLXC | USD CL A ORD SHS | $13,805,400 | 1,297,500 | SH | None |
| ASCENDIS PHARMA A/S | ASND | ORD SHS | $13,336,000 | 50,000 | SH | None |
| KAILERA THERAPEUTICS INC | KLRA | COMMON STOCK | $12,116,500 | 550,000 | SH | None |
| INSMED INC | INSM | COM PAR $.01 | $7,996,500 | 75,000 | SH | None |
| FAETH THERAPEUTICS INC | FTH | COM NEW | $7,655,550 | 1,028,242 | SH | None |
| ENLIVEN THERAPEUTICS INC | ELVN | COM | $7,612,500 | 150,000 | SH | None |
| TARSUS PHARMACEUTICALS INC | TARS | COM | $6,294,000 | 100,000 | SH | None |
| IBIO INC | IBIO | COM NEW | $6,247,500 | 3,570,000 | SH | None |
| CRINETICS PHARMACEUTICALS IN | CRNX | COM | $4,677,500 | 125,000 | SH | None |
| ARCUTIS BIOTHERAPEUTICS INC | ARQT | COM | $4,588,500 | 175,000 | SH | None |
| ARROWHEAD PHARMACEUTICALS IN | ARWR | COM | $4,075,500 | 50,000 | SH | None |
| STRUCTURE THERAPEUTICS INC | GPCR | SPONSORED ADS | $4,025,250 | 75,000 | SH | None |
| RESEARCH ALLIANCE CORP III | Unresolved | ORD SHS CL A | $3,959,000 | 370,000 | SH | None |
| COGENT BIOSCIENCES INC | COGT | COM | $3,870,000 | 100,000 | SH | None |
| ALTIMMUNE INC | ALT | COM NEW | $3,800,000 | 1,250,000 | SH | None |
| AMYLYX PHARMACEUTICALS INC | AMLX | COM | $3,592,000 | 200,000 | SH | None |
| ODYSSEY THERAPEUTICS INC | ODTX | COMMON STOCK | $3,274,250 | 175,000 | SH | None |
| VAXCYTE INC | PCVX | COM | $2,906,500 | 50,000 | SH | None |
| BOUNDLESS BIO INC | BOLD | COM | $2,500,000 | 1,000,000 | SH | None |
| QUINCE THERAPEUTICS INC | QNCX | COM | $100,009 | 5,498 | SH | None |
No matching rows. Clear the filter to see all records.
Largest 50 positions by reported value; the filing may contain more positions.
How amendments affect these holdings
This view uses 1 effective filing version(s). A restatement replaces the previous book; a new-holdings amendment adds positions. 1 positions lack a resolved ticker and 0 positions are put or call entries.
A 13F is a delayed quarterly snapshot of disclosed holdings. It is not a complete trade ledger and does not reveal every position in a manager's portfolio. Option values refer to the reported underlying position rather than a traded option premium.
Quarter end and public filing date
Use the filing's public availability date when constructing a historical observation. The quarter-end report period is earlier and cannot be substituted for when the public learned the holdings.